Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5463-5469

  Sime, Fekade Bruck ^a,b   Roberts, Michael S ^a,b,c   Tiong, Ing Soo ^b,d   Gardner, Julia H ^b   Lehman, Sheila ^b   Peake, Sandra L ^b   Hahn, Uwe ^b   Warner, Morgyn S ^d   Roberts, Jason A ^a,c,e,f  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; GENTAMICIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LIQUID CHROMATOGRAPHY; MALE; MANTLE CELL LYMPHOMA; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY; VOLUME OF DISTRIBUTION AT STEADY-STATE; BLOOD; CLINICAL TRIAL; HEMATOLOGIC NEOPLASMS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED;

AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 84940922583     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00389-15     Document Type: Article

References (45)

1. Tallis E, Rudensky B, Attias D., Raveh D, Schlesinger Y, Yinnon AM 1999. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of Gram-negative bacilli and Staphylococcus aureus. Diagn Microbiol Infect Dis 35:121-126. http://dx.doi.org/10.1016/S0732-8893(99)00062-0.
2. Karlowsky JA, Draghi DC, Jones M.E., Thornsberry C., Friedland IR, Sahm DF. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosaand Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 47:1681-1688. http://dx.doi.org/10.1128/AAC.47.5.1681-1688.2003.
3. Freifeld AG, Bow EJ, Sepkowitz K.A., Boeckh MJ, Ito JI, Mullen CA, Raad I.I., Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-e93. http://dx.doi.org/10.1093/cid/cir073.
4. Averbuch D, Orasch C, Cordonnier C., Livermore DM, Mikulska M, Viscoli C, Gyssens I.C., Kern WV, Klyasova G, Marchetti O, Engelhard D., Akova M. 2013. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98:1826-1835. http://dx.doi.org/10.3324/haematol.2013.091025.
5. Paul M, Yahav D, Fraser A., Leibovici L. 2006. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and metaanalysis of randomized controlled trials. J Antimicrob Chemother 57: 176-189. http://dx.doi.org/10.1093/jac/dki448.
6. Yahav D, Paul M, Fraser A., Sarid N, Leibovici L. 2007. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 7:338-348. http://dx.doi.org/10.1016/S1473-3099(07)70109-3.
7. Kalil AC. 2011. Is cefepime safe for clinical use? A Bayesian viewpoint. J Antimicrob Chemother 66:1207-1209. http://dx.doi.org/10.1093/jac/dkr138.
8. USFDA. 2009. Statistical review and evaluation. Clinical studies NDA no. 50-679. Drug name: Maxipime 04/22/2009. FDA, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/UCM167309.pdf. Accessed 6 February 2015.
9. Kim PW, Wu YT, Cooper C, Rochester G., Valappil T, Wang Y, Kornegay C., Nambiar S. 2010. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51:381-389. http://dx.doi.org/10.1086/655131.
10. Leibovici L, Yahav D, Paul M. 2010. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51:1350-1352. http://dx.doi.org/10.1086/657247.
11. Nguyen TD, Williams B, Trang E. 2009. Cefepime therapy and all-cause mortality. Clin Infect Dis 48:902-904. http://dx.doi.org/10.1086/597264.
12. Leibovici L, Yahav D, Paul M. 2010. Excess mortality related to cefepime. Lancet Infect Dis 10:293-294. http://dx.doi.org/10.1016/S1473-3099(10)70070-0.
13. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12. http://dx.doi.org/10.1086/516284.
14. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin Infect Dis 27:10-22. http://dx.doi.org/10.1086/514622.
15. Abbott IJ, Roberts JA 2012. Infusional beta-lactam antibiotics in febrile neutropenia: has the time come? Curr Opin Infect Dis 25:619-625. http://dx.doi.org/10.1097/QCO.0b013e32835915c2.
16. Lortholary O, Lefort A, Tod M., Chomat AM, Darras-Joly C, Cordonnier C. 2008. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 8:612-620. http://dx.doi.org/10.1016/S1473-3099(08)70228-7.
17. Navas D, Caillon J, Batard E., Le Conte P, Kergueris MF, Moreau P, Potel G. 2006. Trough serum concentrations of beta-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of beta-lactams. Int J Antimicrob Agents 27:102-107. http://dx.doi.org/10.1016/j.ijantimicag.2005.09.016.
18. Hughes WT, Armstrong D, Bodey G.P., Bow EJ, Brown AE, Calandra T, Feld R., Pizzo PA, Rolston KV, Shenep JL, Young LS 2002. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751. http://dx.doi.org/10.1086/339215.
19. Sime FB, Roberts MS, Roberts J.A., Robertson TA. 2014. Simultaneous determination of seven beta-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 960:134-144. http://dx.doi.org/10.1016/j.jchromb.2014.04.029.
20. NATA. October 2013. Guidelines for the validation and verification of quantitative and qualitative test methods. National Association of Testing Authorities, Sydney, Australia. http://www.nata.com.au/nata/phocadownload/publications/Guidance-information/tech-notes-information-papers/technical-note-17.pdf. Accessed 6 February 2015.
21. Barbhaiya RH, Forgue ST, Gleason C.R., Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J., Martin RR. 1992. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 36:552-557. http://dx.doi.org/10.1128/AAC.36.3.552.
22. Zhang Y, Huo M, Zhou J., Xie S. 2010. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99:306-314. http://dx.doi.org/10.1016/j.cmpb.2010.01.007.
23. Wong G, Briscoe S, Adnan S., McWhinney B, Ungerer J, Lipman J., Roberts JA. 2013. Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57:6165-6170. http://dx.doi.org/10.1128/AAC.00951-13.
24. Ulldemolins M, Roberts JA, Rello J, Paterson D.L., Lipman J. 2011. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 50:99-110. http://dx.doi.org/10.2165/11539220-000000000-00000.
25. EUCAST. 1 January 2015. Breakpoint tables for interpretation of MICs and zone diameters. EUCAST, ESCMID, Basel, Switzerland. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/v-5.0-Breakpoint-Table-01.pdf. Accessed 6 February 2015.
26. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
27. Chapuis TM, Giannoni E, Majcherczyk P.A., Chiolero R., Schaller MD, Berger MM, Bolay S, Decosterd L.A., Bugnon D., Moreillon P. 2010. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 14:R51. http://dx.doi.org/10.1186/cc8941.
28. Sampol E, Jacquet A, Viggiano M., Bernini V, Manelli JC, Lacarelle B, Durand A. 2000. Plasma, urine and skin pharmacokinetics of cefepime in burns patients. J Antimicrob Chemother 46:315-317. http://dx.doi.org/10.1093/jac/46.2.315.
29. Tam VH, McKinnon PS, Akins R.L., Drusano GL, Rybak MJ. 2003. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 47: 1853-1861. http://dx.doi.org/10.1128/AAC.47.6.1853-1861.2003.
30. Rich BS, Keel R, Ho V.P., Turbendian H., Afaneh CI, Dakin GF, Pomp A, Nicolau D.P., Barie PS. 2012. Cefepime dosing in the morbidly obese patient population. Obes Surg 22:465-471. http://dx.doi.org/10.1007/s11695-011-0586-8.
31. Hanley MJ, Abernethy DR, Greenblatt DJ 2010. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71-87. http://dx.doi.org/10.2165/11318100-000000000-00000.
32. Udy AA, Baptista JP, Lim N.L., Joynt GM, Jarrett P, Wockner L, Boots R.J., Lipman J. 2014. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med 42:520-527. http://dx.doi.org/10.1097/CCM.0000000000000029.
33. Tam VH, McKinnon PS, Akins R.L., Rybak MJ, Drusano GL. 2002. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50:425-428. http://dx.doi.org/10.1093/jac/dkf130.
34. Lipman J, Wallis SC, Rickard C. 1999. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 43:2559-2561.
35. Lamoth F, Buclin T, Pascual A., Vora S, Bolay S, Decosterd L.A., Calandra T., Marchetti O. 2010. High cefepime plasma concentrations and neurological toxicityinfebrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 54:4360-4367. http://dx.doi.org/10.1128/AAC.01595-08.
36. Smith NL, Freebairn RC, Park M.A., Wallis SC, Roberts JA, Lipman J. 2012. Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Crit Care Resusc 14:312-315.
37. Maganti R, Jolin D, Rishi D., Biswas A. 2006. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 8:312-314. http://dx.doi.org/10.1016/j.yebeh.2005.09.010.
38. Capparelli FJ, Diaz MF, Hlavnika A, Wainsztein N.A., Leiguarda R., Del Castillo ME. 2005. Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. Neurology 65:1840.
39. Nicasio AM, Ariano RE, Zelenitsky S.A., Kim A., Crandon JL, Kuti JL, Nicolau DP. 2009. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 53:1476-1481. http://dx.doi.org/10.1128/AAC.01141-08.
40. Cheatham SC, Shea KM, Healy D.P., Humphrey ML, Fleming MR, Wack MF, Smith D.W., Sowinski KM, Kays MB. 2011. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 37:46-50. http://dx.doi.org/10.1016/j.ijantimicag.2010.08.016.
41. Sime FB, Roberts MS, Tiong I.S., Gardner JH, Lehman S, Peake SL, Hahn U, Warner M.S., Roberts JA. 7 May 2015. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. J Antimicrob Chemother http://dx.doi.org/10.1093/jac/dkv123.
42. Bauer KA, West JE, O'Brien JM, Goff DA. 2013. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 57:2907-2912. http://dx.doi.org/10.1128/AAC.02365-12.
43. Burgess SV, Mabasa VH, Chow I, Ensom MH 2015. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. Ann Pharmacother 49:311-322. http://dx.doi.org/10.1177/1060028014564179.
44. min/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents 45:541-544. http://dx.doi.org/10.1016/j.ijantimicag.2014.12.018.
45. Bhat SV, Peleg AY, Lodise T.P., Jr, Shutt KA, Capitano B, Potoski BA, Paterson DL. 2007. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms. Antimicrob Agents Chemother 51:4390-4395. http://dx.doi.org/10.1128/AAC.01487-06.